Radiopharm Theranostics Ltd

Radiopharm Theranostics Ltd is a research and development company focused on developing and commercializing radiopharmaceutical products for therapeutic and diagnostic applications in precision oncology. The company develops targeted and scientifically validated radiopharmaceutical technologies, which are in both pre-clinical and clinical stages. These technologies encompass peptides, small molecules, and antibodies attached to medical quality radioisotopes. Radiopharm Theranostics Ltd is pursuing registration and marketing approval for its products and therapies in development across the United States, the European Union, the United Kingdom, China, Japan, Australia, and Canada. The company focuses on radiosensitive tumor types, particularly solid tumors with high mortality rates that are difficult to detect and treat, aiming to develop theranostic clinical products that offer more effective detection and treatment than current options. Radiopharm Theranostics Ltd has a pipeline of five licensed platform technologies and a joint venture with MD Anderson in Houston, named "Radiopharm Ventures LLC," established to develop novel radiopharmaceutical products. These novel technologies in development target high unmet medical needs for both diagnostic and therapeutic product candidates. The company intends to advance all its molecules to the clinical stage and increase the number of clinical trials conducted. To support its clinical trials, Radiopharm Theranostics Ltd partners with nuclear medicine suppliers to secure a constant supply of therapeutic isotopes, with plans to maintain and expand these partnerships. The company has also entered into license agreements with universities and institutions for exclusive global use of novel technology to develop its clinical assets.